rBIO, Co.

rBIO is addressing limitations in biomanufacturing with its next-generation platform, which enhances E. coli-based protein expression to maximize insulin production efficiency, scalability, and cost-effectiveness. Unlike traditional recombinant approaches, which often suffer from low expression yields, rBIO’s engineered system optimizes genetic translation mechanisms with synthetic biology to achieve significantly higher protein output. This advancement represents a fundamental shift in biomanufacturing, improving both affordability and accessibility of life-saving biologics.